当前位置: 首页 > 详情页

Cholesterol metabolic reprogramming mediates microglia-induced chronic neuroinflammation and hinders neurorestoration following stroke

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Dept Neurol, Beijing, Peoples R China [2]Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Dept Neurosurg,Inst Translat Med, Shenzhen, Peoples R China [3]Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China [4]Tianjin Huanhu Hosp, Dept Neurol, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Dis, Tianjin, Peoples R China [5]Beijing Municipal Geriatr Med Res Ctr, Beijing, Peoples R China [6]Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
出处:
ISSN:

摘要:
Chronic neuroinflammation is a major obstacle to post-stroke recovery, yet the underlying mechanisms, particularly the link between prolonged microglial activation and cholesterol metabolism, are not fully known. Here we show that ischaemic injury induces persistent microglial activation that perpetuates chronic inflammation, leading to microglial cholesterol accumulation and metabolic reprogramming. Using single-cell RNA sequencing, we identified distinct stroke-associated foamy microglia clusters characterized by extensive reprogramming of cholesterol metabolism. Furthermore, direct intracerebral free cholesterol or cholesterol crystal infusion recapitulated sustained microglial activation, directly linking aberrant cholesterol metabolism to prolonged neuroinflammatory responses. Therapeutically, we demonstrate that reducing microglial cholesterol overload through genetic or pharmacological activation of CYP46A1 in male mice promotes white matter repair and functional recovery. These findings highlight microglial cholesterol metabolism as a key driver of post-stroke inflammation, offering therapeutic strategies targeting cholesterol metabolism to mitigate long-term brain damage and promote neurorestoration, potentially improving stroke-related disability outcomes.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
JCR分区:
出版当年[2023]版:
Q1 ENDOCRINOLOGY & METABOLISM
最新[2024]版:
Q1 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Dept Neurol, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Dept Neurol, Beijing, Peoples R China [5]Beijing Municipal Geriatr Med Res Ctr, Beijing, Peoples R China [6]Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:18261 今日访问量:1 总访问量:1003 更新日期:2025-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院